Merck, Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes at the American Diabetes Association's 76th Scientific Sessions
Charles Gross